Characteristics of hospitalized children with 2009 pandemic influenza A (H1N1): a multicenter study in Korea

J Korean Med Sci. 2012 Apr;27(4):408-15. doi: 10.3346/jkms.2012.27.4.408. Epub 2012 Mar 21.

Abstract

The majority of Korean patients with pandemic influenza A (H1N1) during the 2009 epidemic were under 20 yr of age. The limited data on the clinical characteristics of these children led us to conduct a case note-based investigation of children admitted to 6 university hospitals with 2009 H1N1 influenza. A total of 804 children was enrolled. The median age was 5 yr; 63.8% were males; and 22.4% had at least one chronic underlying disease. Ninety-five of the patients (11.8%) were critically ill and they suffered more from shortness of breath, dyspnea and lymphopenia than the other patients. Among all the patients, 98.8% were treated with antivirals and 73% received treatment within 48 hr of illness onset. All the enrolled patients are alive and appear to have had good outcomes, probably due to the early intervention and antiviral treatment. This study deals with hospitalized children whose diagnoses of influenza A (H1N1) were confirmed, and therefore provides important new information about the clinical patterns of children with influenza A (H1N1) in Korea.

Keywords: Children; Clinical Characteristics; Epidemiology; Korea; Pandemic Influenza A (H1N1).

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Antiviral Agents / therapeutic use
  • Child
  • Child, Hospitalized
  • Child, Preschool
  • Critical Illness
  • Dyspnea / etiology
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Influenza A Virus, H1N1 Subtype / genetics
  • Influenza A Virus, H1N1 Subtype / isolation & purification*
  • Influenza, Human / diagnosis*
  • Influenza, Human / drug therapy
  • Influenza, Human / epidemiology
  • Lymphopenia / etiology
  • Male
  • Oseltamivir / therapeutic use
  • Pandemics
  • Republic of Korea / epidemiology
  • Retrospective Studies

Substances

  • Antiviral Agents
  • Oseltamivir